FDA says Join Josie's website misbranded compounded semaglutide and tirzepatide by falsely implying FDA approval and naming Join Josie as compounder.
What happened
FDA reviewed https://joinjosie.com in December 2025. The letter says the site offers compounded semaglutide and tirzepatide, shows labels naming Join Josie as if it were the compounder, and uses claims that the products contain 'the same active ingredient' as Wegovy and Zepbound. FDA says those statements are false or misleading and make the products misbranded.
What FDA found
Website labels for compounded semaglutide and tirzepatide name Join Josie as the compounder even though the letter says it is not.
FDCA §§ 502(a), 502(bb) [21 U.S.C. §§ 352(a), 352(bb)]; 21 CFR § 201.1(h)(2)Website claims that the products have 'the same active ingredient' as FDA-approved Wegovy and Zepbound imply FDA approval that compounded drugs do not have.
FDCA §§ 502(a), 502(bb) [21 U.S.C. §§ 352(a), 352(bb)]The letter says these misbranded products were introduced or delivered for introduction into interstate commerce.
FDCA § 301(a) [21 U.S.C. § 331(a)]The letter also says receiving or delivering misbranded drugs in interstate commerce is prohibited.
FDCA § 301(c) [21 U.S.C. § 331(c)]
What FDA wants
Within 15 working days, send a written response to CDER's Office of Compounding Quality and Compliance describing steps taken, identifying the entities that produce the products, providing sample labeling, and addressing or correcting the claims.
Who should pay attention
- telehealth companies selling compounded GLP-1 drugs
- compounding pharmacies and contract manufacturers whose labels appear on telehealth sites
- marketing and regulatory teams reviewing drug claims
This is a summary. Read the original letter on fda.gov.